23 Feb Sentien Biotechnologies
Brian Miller, Co-Founder and CEO
Oct. 13 | 2:30pm | BlueRock Therapeutics Ballroom
Sentien Biotechnologies is a privately-held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, integrates allogeneic mesenchymal stromal cells within an extracorporeal, hollow-fiber device. By immobilizing MSCs within a blood-contacting device, SBI-101 enables controlled, dynamic, and sustained delivery of MSC-secreted factors to the patient’s blood, without the need for direct injection of the MSCs themselves. SBI-101 has been evaluated in a Phase Ib/IIa study in subjects with dialysis-requiring acute kidney injury. An interim readout from the clinical study provides evidence of anti-inflammatory and wound healing effects consistent with the SBI-101 therapeutic hypothesis. Building on this initial clinical experience, SBI-101 is also being evaluated in COVID-19 patients suffering from severe systemic inflammation. Sentien’s technology is being explored in additional systemic inflammatory indications in both acute and chronic diseases, focusing on complex conditions where single-factor agents have not been effective.